Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

Mathilde Ruggiu; Florence Oberkampf; David Ghez; Pascale Cony-Makhoul; Florence Beckeriche; Isabelle Cano; Anne L. Taksin; Omar Benbrahim; Stéphanie Ghez; Hassan Farhat; Sophie Rigaudeau; Noémie de Gunzburg; Diane Lara; Christine Terre; Victoria Raggueneau; Isabel Garcia; Marc Spentchian; Stéphane De Botton; Philippe Rousselot

doi:10.1080/10428194.2017.1397666

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

Mathilde Ruggiu, Florence Oberkampf, David Ghez, Pascale Cony-Makhoul, Florence Beckeriche, Isabelle Cano, Anne L. Taksin, Omar Benbrahim, Stéphanie Ghez, Hassan Farhat, Sophie Rigaudeau, Noémie de Gunzburg, Diane Lara, Christine Terre, Victoria Raggueneau, Isabel Garcia, Marc Spentchian, Stéphane De Botton, Philippe Rousselot

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Although the tyrosine kinase inhibitor (TKI) era has brought great improvement in outcome in chronic myelogenous leukemia (CML), prognosis of accelerated phase or myeloid blast crisis patients or of de novo Philadelphia chromosome-positive acute myeloid leukemia remains poor. We conducted a retrospective study on patients with advanced phase disease treated with a TKI and azacytidine. Sixteen patients were eligible. Median age was 64.9 years, the median number of previous therapies was 2.5 lines, and median follow-up was 23.1 months. Hematologic response (HR) rate was 81.3%. Median overall survival (OS), event free survival and relapse-free survival (RFS) were 31.5, 23.3, and 32.2 months, respectively. All except one patient were treated as out-patients after the first cycle. Five patients were bridged to allogenic hematopoietic stem cells transplant. The combination of a TKI and azacytidine is a safe and efficient regiment for patients with CML patients in advanced phases.

Original language	English
Pages (from-to)	1659-1665
Number of pages	7
Journal	Leukemia and Lymphoma
Volume	59
Issue number	7
DOIs	https://doi.org/10.1080/10428194.2017.1397666
Publication status	Published - 3 Jul 2018

Keywords

Advanced phase CML
azacytidine
tyrosine kinase inhibitors

Access to Document

10.1080/10428194.2017.1397666

Cite this

Ruggiu, M., Oberkampf, F., Ghez, D., Cony-Makhoul, P., Beckeriche, F., Cano, I., Taksin, A. L., Benbrahim, O., Ghez, S., Farhat, H., Rigaudeau, S., de Gunzburg, N., Lara, D., Terre, C., Raggueneau, V., Garcia, I., Spentchian, M., De Botton, S., & Rousselot, P. (2018). Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. Leukemia and Lymphoma, 59(7), 1659-1665. https://doi.org/10.1080/10428194.2017.1397666

@article{b25130c5331c48d0b513d1df7d3efd15,

title = "Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia",

abstract = "Although the tyrosine kinase inhibitor (TKI) era has brought great improvement in outcome in chronic myelogenous leukemia (CML), prognosis of accelerated phase or myeloid blast crisis patients or of de novo Philadelphia chromosome-positive acute myeloid leukemia remains poor. We conducted a retrospective study on patients with advanced phase disease treated with a TKI and azacytidine. Sixteen patients were eligible. Median age was 64.9 years, the median number of previous therapies was 2.5 lines, and median follow-up was 23.1 months. Hematologic response (HR) rate was 81.3%. Median overall survival (OS), event free survival and relapse-free survival (RFS) were 31.5, 23.3, and 32.2 months, respectively. All except one patient were treated as out-patients after the first cycle. Five patients were bridged to allogenic hematopoietic stem cells transplant. The combination of a TKI and azacytidine is a safe and efficient regiment for patients with CML patients in advanced phases.",

keywords = "Advanced phase CML, azacytidine, tyrosine kinase inhibitors",

author = "Mathilde Ruggiu and Florence Oberkampf and David Ghez and Pascale Cony-Makhoul and Florence Beckeriche and Isabelle Cano and Taksin, {Anne L.} and Omar Benbrahim and St{\'e}phanie Ghez and Hassan Farhat and Sophie Rigaudeau and {de Gunzburg}, No{\'e}mie and Diane Lara and Christine Terre and Victoria Raggueneau and Isabel Garcia and Marc Spentchian and {De Botton}, St{\'e}phane and Philippe Rousselot",

note = "Publisher Copyright: {\textcopyright} 2017, {\textcopyright} 2017 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2018",

month = jul,

day = "3",

doi = "10.1080/10428194.2017.1397666",

language = "English",

volume = "59",

pages = "1659--1665",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "7",

}

Ruggiu, M, Oberkampf, F, Ghez, D, Cony-Makhoul, P, Beckeriche, F, Cano, I, Taksin, AL, Benbrahim, O, Ghez, S, Farhat, H, Rigaudeau, S, de Gunzburg, N, Lara, D, Terre, C, Raggueneau, V, Garcia, I, Spentchian, M, De Botton, S & Rousselot, P 2018, 'Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia', Leukemia and Lymphoma, vol. 59, no. 7, pp. 1659-1665. https://doi.org/10.1080/10428194.2017.1397666

TY - JOUR

T1 - Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

AU - Ruggiu, Mathilde

AU - Oberkampf, Florence

AU - Ghez, David

AU - Cony-Makhoul, Pascale

AU - Beckeriche, Florence

AU - Cano, Isabelle

AU - Taksin, Anne L.

AU - Benbrahim, Omar

AU - Ghez, Stéphanie

AU - Farhat, Hassan

AU - Rigaudeau, Sophie

AU - de Gunzburg, Noémie

AU - Lara, Diane

AU - Terre, Christine

AU - Raggueneau, Victoria

AU - Garcia, Isabel

AU - Spentchian, Marc

AU - De Botton, Stéphane

AU - Rousselot, Philippe

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Although the tyrosine kinase inhibitor (TKI) era has brought great improvement in outcome in chronic myelogenous leukemia (CML), prognosis of accelerated phase or myeloid blast crisis patients or of de novo Philadelphia chromosome-positive acute myeloid leukemia remains poor. We conducted a retrospective study on patients with advanced phase disease treated with a TKI and azacytidine. Sixteen patients were eligible. Median age was 64.9 years, the median number of previous therapies was 2.5 lines, and median follow-up was 23.1 months. Hematologic response (HR) rate was 81.3%. Median overall survival (OS), event free survival and relapse-free survival (RFS) were 31.5, 23.3, and 32.2 months, respectively. All except one patient were treated as out-patients after the first cycle. Five patients were bridged to allogenic hematopoietic stem cells transplant. The combination of a TKI and azacytidine is a safe and efficient regiment for patients with CML patients in advanced phases.

AB - Although the tyrosine kinase inhibitor (TKI) era has brought great improvement in outcome in chronic myelogenous leukemia (CML), prognosis of accelerated phase or myeloid blast crisis patients or of de novo Philadelphia chromosome-positive acute myeloid leukemia remains poor. We conducted a retrospective study on patients with advanced phase disease treated with a TKI and azacytidine. Sixteen patients were eligible. Median age was 64.9 years, the median number of previous therapies was 2.5 lines, and median follow-up was 23.1 months. Hematologic response (HR) rate was 81.3%. Median overall survival (OS), event free survival and relapse-free survival (RFS) were 31.5, 23.3, and 32.2 months, respectively. All except one patient were treated as out-patients after the first cycle. Five patients were bridged to allogenic hematopoietic stem cells transplant. The combination of a TKI and azacytidine is a safe and efficient regiment for patients with CML patients in advanced phases.

KW - Advanced phase CML

KW - azacytidine

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85035151668&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1397666

DO - 10.1080/10428194.2017.1397666

M3 - Article

C2 - 29179634

AN - SCOPUS:85035151668

SN - 1042-8194

VL - 59

SP - 1659

EP - 1665

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

Abstract

Keywords

Access to Document

Other files and links

Cite this